DK2155169T3 - Formulation of nevirapine extended release - Google Patents

Formulation of nevirapine extended release Download PDF

Info

Publication number
DK2155169T3
DK2155169T3 DK08756672.5T DK08756672T DK2155169T3 DK 2155169 T3 DK2155169 T3 DK 2155169T3 DK 08756672 T DK08756672 T DK 08756672T DK 2155169 T3 DK2155169 T3 DK 2155169T3
Authority
DK
Denmark
Prior art keywords
nevirapine
formulation
tablets
granulation
tablet
Prior art date
Application number
DK08756672.5T
Other languages
Danish (da)
English (en)
Inventor
Michael L Cappola
Svetlana Sienkiewicz
Glenn Charles Snow
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2155169(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK2155169T3 publication Critical patent/DK2155169T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08756672.5T 2007-06-08 2008-06-04 Formulation of nevirapine extended release DK2155169T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08
PCT/US2008/065705 WO2008154234A2 (fr) 2007-06-08 2008-06-04 Formulation à libération prolongée de névirapine

Publications (1)

Publication Number Publication Date
DK2155169T3 true DK2155169T3 (en) 2016-06-13

Family

ID=39739795

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08756672.5T DK2155169T3 (en) 2007-06-08 2008-06-04 Formulation of nevirapine extended release

Country Status (29)

Country Link
US (1) US8460704B2 (fr)
EP (1) EP2155169B1 (fr)
JP (1) JP5417662B2 (fr)
KR (1) KR101017862B1 (fr)
CN (1) CN101784263B (fr)
AR (1) AR066924A1 (fr)
AU (1) AU2008262031B2 (fr)
BR (1) BRPI0811732A2 (fr)
CA (1) CA2687491C (fr)
CL (1) CL2008001678A1 (fr)
CO (1) CO6150128A2 (fr)
DK (1) DK2155169T3 (fr)
EA (1) EA018377B1 (fr)
EC (1) ECSP099561A (fr)
ES (1) ES2574836T3 (fr)
HK (1) HK1145806A1 (fr)
HU (1) HUE028598T2 (fr)
IL (1) IL199924A0 (fr)
MA (1) MA31430B1 (fr)
MX (1) MX2009007764A (fr)
NZ (1) NZ578664A (fr)
PE (2) PE20090371A1 (fr)
PL (1) PL2155169T3 (fr)
TN (1) TN2009000510A1 (fr)
TW (1) TWI419716B (fr)
UA (1) UA97971C2 (fr)
UY (1) UY31128A1 (fr)
WO (1) WO2008154234A2 (fr)
ZA (1) ZA200904939B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CN101784263B (zh) 2007-06-08 2012-11-07 贝林格尔.英格海姆国际有限公司 奈韦拉平的延长释放制剂
EP2307038A4 (fr) 2008-06-27 2013-03-27 Univ Duke Agents thérapeutiques comprenant des peptides de type élastine
AU2012264475A1 (en) 2011-05-30 2013-10-31 Cipla Limited Pharmaceutical antiretroviral composition
EP4295858A1 (fr) * 2011-08-24 2023-12-27 ImmunoForge Co., Ltd. Formulations des principes actifs destinées à la libération prolongée
US20150104511A1 (en) * 2012-03-05 2015-04-16 Cipla Limited Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine
CN104523630B (zh) * 2015-01-22 2017-08-25 山东新时代药业有限公司 一种奈韦拉平片剂
EP3153157A1 (fr) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Composition pharmaceutique à libération prolongée de névirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (fr) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines et leur utilisation pour la prevention ou le traitement de l'infection par le hiv
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DE69805001T2 (de) * 1997-12-05 2002-08-22 Alza Corp Osmotische darreichungsform mit zwei mantelschichten
DE69915346T2 (de) * 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
ATE313319T1 (de) * 1999-03-31 2006-01-15 Janssen Pharmaceutica Nv Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe
IL148801A0 (en) * 1999-09-24 2002-09-12 Janssen Pharmaceutica Nv Antiviral compositions
AU2084801A (en) 1999-12-09 2001-06-18 Alza Corporation Antiviral medication
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (fr) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Utilisation de nevirapine pour traiter ou prevenir des pathologies lipidiques chez des patients presentant une infection par vih resistante a la nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
AU2003287666A1 (en) 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
CA2529852A1 (fr) 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions et procedes de traitement du vih
EA008944B1 (ru) 2003-10-01 2007-10-26 Люпин Лимитед Фармацевтическая композиция управляемого высвобождения и способ ее получения
NZ547619A (en) 2003-11-13 2009-06-26 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
CA2577288C (fr) * 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2006114709A1 (fr) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Compositions pharmaceutiques d'antiretroviraux
JP2009500318A (ja) 2005-06-29 2009-01-08 パナセア バイオテック リミテッド 新規な徐放性医薬組成物とその製法
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
JP2009511191A (ja) * 2005-10-14 2009-03-19 マイクロドース・テクノロジーズ・インコーポレーテッド 経口投与剤組合せ型医薬パッケージ法
CN101784263B (zh) 2007-06-08 2012-11-07 贝林格尔.英格海姆国际有限公司 奈韦拉平的延长释放制剂

Also Published As

Publication number Publication date
US20100278918A1 (en) 2010-11-04
KR101017862B1 (ko) 2011-03-04
EA200900958A1 (ru) 2010-04-30
PE20131035A1 (es) 2013-10-01
US8460704B2 (en) 2013-06-11
MX2009007764A (es) 2009-09-10
PL2155169T3 (pl) 2016-09-30
TW200916127A (en) 2009-04-16
EP2155169A2 (fr) 2010-02-24
ECSP099561A (es) 2009-09-29
UY31128A1 (es) 2009-01-30
NZ578664A (en) 2011-11-25
CA2687491C (fr) 2011-09-20
EP2155169B1 (fr) 2016-03-23
CN101784263B (zh) 2012-11-07
WO2008154234A2 (fr) 2008-12-18
CL2008001678A1 (es) 2009-09-11
UA97971C2 (ru) 2012-04-10
KR20100020447A (ko) 2010-02-22
MA31430B1 (fr) 2010-06-01
JP2010520891A (ja) 2010-06-17
IL199924A0 (en) 2010-04-15
HUE028598T2 (en) 2016-12-28
ES2574836T3 (es) 2016-06-22
JP5417662B2 (ja) 2014-02-19
CA2687491A1 (fr) 2008-12-18
AR066924A1 (es) 2009-09-23
AU2008262031B2 (en) 2011-08-25
EA018377B1 (ru) 2013-07-30
TWI419716B (zh) 2013-12-21
AU2008262031A1 (en) 2008-12-18
CN101784263A (zh) 2010-07-21
WO2008154234A9 (fr) 2009-11-26
BRPI0811732A2 (pt) 2014-11-18
CO6150128A2 (es) 2010-04-20
ZA200904939B (en) 2010-04-28
HK1145806A1 (en) 2011-05-06
TN2009000510A1 (en) 2011-03-31
PE20090371A1 (es) 2009-04-24
WO2008154234A3 (fr) 2010-01-21

Similar Documents

Publication Publication Date Title
DK2155169T3 (en) Formulation of nevirapine extended release
KR100728846B1 (ko) 약물 함유량이 높은 정제
KR100765580B1 (ko) 데페라시록스 분산성 정제
AU2010313571B2 (en) Solid pharmaceutical compositions containing an integrase inhibitor
JP2017501201A (ja) Ａｚｄ９２９１を含む医薬組成物
EP2749270B1 (fr) Racécadotril et ses compositions pharmaceutiques
WO2004054574A1 (fr) Medicament solide administre par voie orale
CN110913843B (zh) 药物组合物
KR20230028288A (ko) 돌루테그라비르를 포함하는 분산성 정제 제제
Syed et al. Statistical designing and characterization of valsartan oral disintegrating tablet
KR20230008913A (ko) 알펠리십을 포함하는 제약 조성물
Singroli et al. FORMULATION DEVELOPMENT AND EVALUATION OF FAST DISSOLVING TABLETS OF AN ANTI-DEPRESSION DRUG
Desireddy et al. Preparation and Evaluation of Ondansetron Hydrochloride Fast Dissolving Tablets
NZ760868B2 (en) A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin